NasdaqGS:ACADBiotechs
R&D Leadership Transition and Trial Continuity Could Be A Game Changer For ACADIA Pharmaceuticals (ACAD)
In late April, ACADIA Pharmaceuticals announced that Head of Research and Development Elizabeth H.Z. Thompson, Ph.D., will retire for personal reasons but remain in her role until a successor is named and continue as a consultant through at least the end of 2026, supporting continuity around key remlifanserin Phase 2 and early Phase 3 milestones.
This planned transition, alongside confirmation that all ongoing trials such as the Phase 2 studies of remlifanserin in Alzheimer’s disease...